However, it was striking that one-third of patients in CR/CRi, harbored IDH1/2 mutations, consistent with later reports of venetoclax combination therapy in treatment-naïve AML reaffirming the sensitivity of IDH1/2 mutated patients to venetoclax-based therapy22–24. Here, IDH1 is linked to acute myeloid leukemia.